the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
Published 4 months ago • 148 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:22
real-world outcomes following dose reduction of first-line ibrutinib in patients with wm
-
2:24
the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
-
1:56
ibrutinib treatment and its associated risk factors
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
6:24
indiko biochemistry analyzer demonstration
-
21:13
breakthrough cll treatments: the latest advances in chronic lymphocytic leukemia | the patient story
-
3:52
blood volume monitoring animation - crit-line® technology
-
3:34
dose-escalation results from phase ib/iia trial of azd4573 acalabrutinib in r/r dlbcl
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
3:58
five-year follow up of the uk cll forum ibrutinib data
-
2:54
the duo trial: dose modifications on response to duvelisib in patients with sll/cll
-
0:45
difference between quality of life & patient-reported outcomes
-
1:29
bellwave-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve cll/sll
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:02
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
2:42
the role of ibrutinib in dlbcl and the value of next-generation btk inhibitors
-
3:27
the safety and efficacy of acalabrutinib for the treatment of r/r mzl
-
1:51
efficacy of odronextamab in r/r dlbcl & determining the optimal sequencing of immune therapies